Amyloidosis is a group of disorders characterised by extracellular deposition of insoluble fibrillary proteins known as amyloid fibrils. Light chain amyloidosis (AL) is the most aggressive form and is caused by the accumulation of monoclonal immunoglobulin light chains secondary to B-cell dyscrasia. The heart is affected in up to 90% of cases, and more than half of patients present with heart failure (HF) symptoms. Accumulation of amyloid fibrils causes the myocardial wall to thicken and stiffen leading to the development of restrictive cardiomyopathy (RCM). Despite treatment with chemotherapy, the median survival rate in AL amyloidosis and HF is less than six months. A 57-year-old female without previous cardiac history sought medical attention due to rapid and progressive dispone and signs of right ventricular ( . The diagnosis of RCM was made and she underwent RV endomyocardial biopsy (EMB), which revealed massive fibrosis but was otherwise unspecific. Similarly, bone marrow biopsy was negative. Conventional HF treatment with beta-blockers, angiotensin converting enzyme-inhibitors, and diuretics did not improve the patient's status and she was send to our centre. Despite non-diagnostic RV-EMB, the rapid course, laboratory findings, and imaging convinced us to undertake LV-EMB. The histopathology revealed a large amount of amorphous substance between tightly squeezed myocytes (Fig.
Amyloidosis is a group of disorders characterised by extracellular deposition of insoluble fibrillary proteins known as amyloid fibrils. Light chain amyloidosis (AL) is the most aggressive form and is caused by the accumulation of monoclonal immunoglobulin light chains secondary to B-cell dyscrasia. The heart is affected in up to 90% of cases, and more than half of patients present with heart failure (HF) symptoms. Accumulation of amyloid fibrils causes the myocardial wall to thicken and stiffen leading to the development of restrictive cardiomyopathy (RCM). Despite treatment with chemotherapy, the median survival rate in AL amyloidosis and HF is less than six months. A 57-year-old female without previous cardiac history sought medical attention due to rapid and progressive dispone and signs of right ventricular (RV) congestion (ascites, peripheral oedemas, hepatomegaly). Prior medical history included: chronic kidney disease advanced to the . The diagnosis of RCM was made and she underwent RV endomyocardial biopsy (EMB), which revealed massive fibrosis but was otherwise unspecific. Similarly, bone marrow biopsy was negative. Conventional HF treatment with beta-blockers, angiotensin converting enzyme-inhibitors, and diuretics did not improve the patient's status and she was send to our centre. Despite non-diagnostic RV-EMB, the rapid course, laboratory findings, and imaging convinced us to undertake LV-EMB. The histopathology revealed a large amount of amorphous substance between tightly squeezed myocytes ( Fig. 1 ) and widespread fibrosis (Fig. 2) . Characteristic apple-green birefringence of the samples, stained with Congo red, were seen under a polarising microscope, which was diagnostic for cardiac amyloidosis. In order to determine the amyloid precursor protein, the immunohistochemistry (anti-bodies against immunoglobulins light chains) has been performed, which confirmed kappa and lambda free light chains (Fig. 3) . Systemic chemotherapy with bortezomib, melphalan, and dexamethasone was initiated. However, due to toxicity, the therapy was changed to low-dose thalidomide, cyclophosphamide, and dexamethasone. Unfortunately, the patient's clinical status gradually deteriorated leading to death five months after the onset of symptoms. 
